iprs000193
10.3205/iprs000193
urn:nbn:de:0183-iprs0001938
Case Report
Recurrence of Acne inversa of the penis – two-stage reconstruction with MatriDerm<Superscript>®</Superscript> and split-thickness skin graft
Rezidiv peniler Acne inversa – Zwei-Stufen-Rekonstruktion mit MatriDerm® und Spalthauttransplantation
Nicklas
Nicklas
Antek
A
Dr. med.
University Center for Orthopedics, Trauma and Plastic Surgery, Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, GermanyUniversity Center for Orthopedics, Trauma and Plastic Surgery, Department of Plastic and Hand Surgery, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany
Antek.nicklas@uniklinikum-dresden.de
author
Stefan
Stefan
Vlad
V
University Center for Orthopedics, Trauma and Plastic Surgery, Department of Plastic and Hand Surgery, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany
author
Dragu
Dragu
Adrian
A
University Center for Orthopedics, Trauma and Plastic Surgery, Department of Plastic and Hand Surgery, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany
author
German Medical Science GMS Publishing House
Düsseldorf
610
Acne inversa
penis reconstruction
STSG
CEM
MatriDerm
Acne inversa
Penisrekonstruktion
Spalthauttransplantation
CEM
MatriDerm
20251222
engl
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).
2193-8091
14
GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW
GMS Interdiscip Plast Reconstr Surg DGPW
04
Hintergrund: Die Autoren berichten über einen Fall eines 42-jährigen männlichen Patienten, der fünf Jahre nach einer Spalthauttransplantation ohne Verwendung einer Kollagen-Elastin-Matrix (CEM) ein Rezidiv einer penilen Acne Inversa hatte. Nach unzureichender pharmakologischer Behandlung wurden eine Resektion der betroffenen Haut, Vakuumtherapie (NPWT), die Anwendung von CEM und eine Spalthauttransplantation (STSG) in mehreren Schritten durchgeführt.Methoden: Es wurde zunächst ein radikales Debridement durchgeführt, gefolgt von einer Unterdrucktherapie. Nach Erreichung eines sauberen Wundbettes wurde eine CEM (1 mm MatriDerm®; MedSkin Solutions Dr. Suwelack AG, Deutschland) angewendet, gefolgt von einer Spalthauttransplantation.Ergebnisse: Nach einem 19-monatigen Follow-up zeigte der Patient ein sehr gutes funktionelles und kosmetisches Ergebnis. Unter intravenöser Antibiotikatherapie und intensiver Wundpflege wurde der vollständige, rezidivfreie Zustand im Genitalbereich beim 19-monatigen Follow-up erreicht. Die subjektive Lebensqualität verdoppelte sich fast von 3,2 auf 9,3 auf der Numerischen Analogskala (NAS).Schlussfolgerung: Komplexe Rekonstruktionsverfahren bei penilen Defekten infolge von Acne inversa können vermieden werden, wenn ein gut durchblutetes Wundbett vorhanden ist. Die Defektdeckung mit MatriDerm® und Spalthauttransplantation kann zu langfristig ästhetisch zufriedenstellenden Ergebnissen mit hoher Patientenzufriedenheit führen. Wir haben einen Patienten über 19 Monate beobachtet, bei dem eine stabile Weichteildeckung des Penis ohne Anzeichen eines Rezidivs vorlag. Wir gehen davon aus, dass die Deckung peniler Defekte mit MatriDerm® und Spalthauttransplantaten ein Rezidiv mit der Notwendigkeit einer komplexen Rekonstruktion verhindern oder zumindest zeitlich verzögern kann.
Background: The authors report a case of a 42-year-old male patient who presented with a relapse of penile acne inversa five years after a split-thickness skin graft without use of collagen-elastin-matrix (CEM). After unsatisfactory pharmacological treatment, resection of the affected skin, negative pressure wound therapy (NPWT), CEM application, and split-thickness skin graft (STSG) were performed in several steps.Methods: We performed initial debridement and consecutive NPWT. After achieving a clean wound bed, a CEM (1 mm MatriDerm®; MedSkin Solutions Dr. Suwelack AG, Germany) was applied, followed by split-thickness skin grafting.Results: During a 19-month follow-up, the patient presented with a very good functional and cosmetic outcome. Under intravenous antibiotic therapy and intensive wound care, we achieved complete recurrence-free status in the genital area at the 19-month follow-up. The subjective quality of life almost tripled from 3.2 to 9.3 on the numeric analog scale (NAS).Conclusion: Complex reconstruction procedures of penile defects i<![CDATA[n a</PlainText></TextGroup>cne inversa can be avoided if there is a well-perfused wound bed. Coverage of the defect with MatriDerm<Superscript>®</Superscript> and split-thickness skin grafting may lead to long-term aesthetically satisfactory results with high patient satisfaction. We have monitored one patient over 19 months, who presented with stable penile soft tissue coverage and no signs of relapse. We anticipate that coverage of penile defects using MatriDerm<Superscript>®</Superscript> and split-thickness skin grafts may prevent or at least delay the need for complex reconstruction in cases of recurrence.</Pgraph></Abstract>
<TextBlock name="Introduction" linked="yes">
<MainHeadline>Introduction</MainHeadline><Pgraph>Acne inversa (also known as Hidradenitis suppurativa) is a rare, chronic debilitating inflammatory skin disease. According to the Dessauer definition, it is a deeply localized, painful inflammatory skin lesion that occurs in areas rich in apocrine glands, particularly in the axillary and inguinal or anogenital regions <TextLink reference="1"></TextLink>, <TextLink reference="2"></TextLink>. In older studies, the prevalence of acne inversa was reported to be 0.4 and 4% <TextLink reference="3"></TextLink>. In a representative study of the French population, the prevalence was reported to be 1% <TextLink reference="4"></TextLink>. Penile manifestations with the extreme variant of elephantiasis are much rarer and are considered a rarity. The male-to-female ratio for acne inversa ranged from 1:2.7 to 1:3.3 <TextLink reference="4"></TextLink>, <TextLink reference="5"></TextLink>, <TextLink reference="6"></TextLink>. In contrast, men are more commonly affected in the perineal region <TextLink reference="7"></TextLink>. The average age at first manifestation is 23 years <TextLink reference="3"></TextLink>.</Pgraph><Pgraph>The pathogenesis of the disease is multifactorial and not fully understood. Some authors attribute bacterial superinfections of ingrown hair follicles to be the cause <TextLink reference="8"></TextLink>. While others consider blockages of apocrine sweat glands to be responsible for the subsequent granulomatous inflammation <TextLink reference="7"></TextLink>. Risk factors include smoking and obesity, which are associated with a more severe course <TextLink reference="6"></TextLink>. The Hurley staging system was developed as a way to classify the severity of Hidradenitis Suppurativa (HS) symptoms. It consists of three stages that help to track the progression of HS and guide treatment decisions: Stage 1: Solitary or multiple isolated abscess formation without scarring or sinus tracts. Stage 2: Recurrent abscesses, single or multiple widely separated lesions, with sinus tract formation. Stage 3: Diffuse or broad involvement, with multiple interconnected sinus tracts and abscesses <TextLink reference="9"></TextLink>.</Pgraph><Pgraph>Surgical intervention remains the best treatment option for severe cases from Stage II onwards. In Stage I and preoperatively, topical therapies and laser treatments are possible and recommended options <TextLink reference="10"></TextLink>, <TextLink reference="11"></TextLink>. </Pgraph><Pgraph>The defect coverage of complex wounds generally follows the reconstructive ladder, which has evolved into the reconstructive elevator <TextLink reference="12"></TextLink>, <TextLink reference="13"></TextLink>. Adhering to these principles, starting with the simplest procedure, is essential when planning defect coverage. Although complex wounds, especially in patients with acne inversa, can be treated with complex, resource-intensive, and expensive flaps such as fascio-myocutaneous Dartos flaps. Simpler therapy options with adjunctive provide good alternatives that can be performed easier and do not require microsurgical expertise. The reason for using a CEM, such as MatriDerm<Superscript>®</Superscript> (MedSkin Solutions Dr. Suwelack AG, Germany) lies in its ability to support the growth of keratinocytes and fibroblasts, mitigate scar contractures in stress zones <TextLink reference="14"></TextLink>, <TextLink reference="15"></TextLink>, <TextLink reference="16"></TextLink>.</Pgraph><Pgraph>The use of MatriDerm<Superscript>®</Superscript> for the reconstruction of various soft tissue defects is well documented in the literature <TextLink reference="17"></TextLink>, <TextLink reference="18"></TextLink>, <TextLink reference="19"></TextLink>. Regarding long-term outcomes, earlier studies have shown that compared to other dermal substitute materials such as Integra<Superscript>®</Superscript> (Integra Lifescience Corporation, Plainsboro, New Jersey, USA), MatriDerm<Superscript>®</Superscript> is more frequently associated with scar contractures but less often with foreign body reactions <TextLink reference="9"></TextLink>.</Pgraph><Pgraph>In the present case, it concerns a recurrence of acne inversa in the sensitive urogenital area – an indication for which there is currently little data on the use of MatriDerm<Superscript>®</Superscript>. An exception is the study by Ludolph et al., which documents the successful use of MatriDerm<Superscript>®</Superscript> in acne inversa-associated and Fournier’s gangrene-associated defects in the urogenital region, achieving good functional and aesthetic results <TextLink reference="20"></TextLink>.</Pgraph><Pgraph>Furthermore, collagen-elastin matrices (CEM) hav<TextGroup><PlainText>e a</PlainText></TextGroup>lready been used more frequently in urogenital reconstructive surgery in general, especially in complex urethral strictures, where the matrix serves as dermal substitute tissue to support coverage after plastic expansion <TextLink reference="21"></TextLink>. These positive experiences from related indications underscore the potential of MatriDerm<Superscript>®</Superscript> in reconstructive procedures following extensive excisions due to acne inversa recurrence.</Pgraph><Pgraph>We present the case of a 42-year-old male patient <TextGroup><PlainText>with a</PlainText></TextGroup> recurrence of penile acne inversa, five years after radical excision and split-thickness skin grafting without the application of a CEM matrix. After exhausting conservative therapy and in the context of the recurrence, the patient reported increasing psychological limitations in his daily life. We performed another radical debridement, <TextGroup><PlainText>NPWT at</PlainText></TextGroup> –75 mmHg (3M™), and the application of 1 mm monol<TextGroup><PlainText>ayer M</PlainText></TextGroup>atriDerm<Superscript>®</Superscript> followed by STSG.</Pgraph></TextBlock>
<TextBlock name="Material and methods" linked="yes">
<MainHeadline>Material and methods</MainHeadline><Pgraph>The patient presented with a recurrence of acne inversa in the penile area, five years after the initial surgery (Figure 1 <ImgLink imgNo="1" imgType="figure" />). The disease had been present in the patient for seven years with progressive findings. Other affected areas include both axillae. The condition is classified as stage III in the Hurley classification. The diagnosis had been histologically confirmed five years earlier. Topical treatments by the involved dermatologists did not lead to any improvement.</Pgraph><Pgraph>Initially, we performed radical debridement of all altered skin areas up to the inner foreskin and started NPWT (Figure 2 <ImgLink imgNo="2" imgType="figure" />). After five days, another debridement was performed along with full-thickness skin grafting and additive NPWT. After removing the vacuum dressing, the full-thickness skin graft showed partial necrosis.</Pgraph><Pgraph>We performed another tangential debridement and the application of 1-mm monolayer MatriDerm<Superscript>®</Superscript> without suturing. Subsequently, we restarted NPWT for another seven days. With a well-granulated wound bed and fully integrated MartiDerm<Superscript>®</Superscript>, the STSG (0.3 mm thickness; MESH ratio 1:1, harvested from left thigh) was performed, followed by another vacuum therapy (Figure 3 <ImgLink imgNo="3" imgType="figure" />). After removing the vacuum dressing after five days, the split-thickness skin was 95% adherent and healed (Figure 4 <ImgLink imgNo="4" imgType="figure" />).</Pgraph><Pgraph>The total hospital stay was 38 days, during which five operations under general anesthesia were performed. Check-ups were conducted at 2 weeks, 4 weeks, <TextGroup><PlainText>3 m</PlainText></TextGroup>onths, 6 months (Figure 5 <ImgLink imgNo="5" imgType="figure" />), and 12 months (<TextGroup><PlainText>Figure 6 </PlainText></TextGroup><ImgLink imgNo="6" imgType="figure" />).</Pgraph><Pgraph>At the last follow-up after 12 months, there was no indication of a recurrence in the penile area. The patient’s preoperative and postoperative quality of life was assessed using the Numeric Analog Scale (NAS).</Pgraph></TextBlock>
<TextBlock name="Results" linked="yes">
<MainHeadline>Results</MainHeadline><Pgraph>The average duration of the five performed operations was 64 minutes. During the hospital stay, we administered antibiotic therapy with Cefuroxime 1.5 g intravenously three times a day for 14 days, followed by Ciprofloxacin 750 mg per os twice a day for another four days. These antibiotics were used targeted to the pathogen upon detection of<Mark2> Staphylococcus aureus</Mark2>. The same spectrum of pathogens had already been identified five years earlier.</Pgraph><Pgraph>In the histopathological examination the diagnosis of acne inversa (Hurley III), made five years earlier, was again confirmed. No recurrence in the penile area occurred 19 months postoperatively. Conservative therapy in the axillary areas on both sides also resulted in a subjective improvement.</Pgraph><Pgraph>At the follow-up examination, the patient showed a very good functional and cosmetic outcome, allowing even the resumption of a normal sex life. His subjective quality of life value on the NAS almost tripled from 3.2 to 9.3.</Pgraph></TextBlock>
<TextBlock name="Discussion" linked="yes">
<MainHeadline>Discussion</MainHeadline><Pgraph>Plastic surgical reconstructions in patients with stage III acne inversa according to Hurley present a significant challenge for the surgeon. The use of MatriDerm<Superscript>®</Superscript> in combination with a staged split-thickness skin grafting represents a simple reconstruction option with a decreased risk of recurrence. Reconstructions in the penile area for acne inversa patients using MatriDerm<Superscript>®</Superscript> and split-thickness skin grafts have not been previously described. Particularly due to the need for dermal elasticity during erection, the use of collagen-elastin matrices is a good choice to ensure erection without an extra tension. Previous studies from our clinic also suggest that the staged application of MatriDerm<Superscript>®</Superscript> in such areas appears to be effective. The significant improvement in the patient’s quality of life described in our case demonstrates that the use of MatriDerm<Superscript>®</Superscript> followed by split-thickness skin grafting leads to a good outcome in this rare disease.</Pgraph><Pgraph>In case of secondary failure of simple reconstruction using CEM and split-thickness skin grafts, larger reconstructions, such as fascio-myocutaneous Dartos flaps, which have significantly higher donor site morbidity, can still be used later. However, the prerequisite for a successful reconstruction with CEM and split-thickness skin graft remains the radical debridement with a complete excision of the affected skin areas and subcutaneous tissue including glandular tissue <TextLink reference="22"></TextLink>, <TextLink reference="23"></TextLink>. Additionally, the application of NPWT before and after CEM application is sensible and established to ensure the integration of the CEM <TextLink reference="16"></TextLink>. In addition, the guideline-compliant antibiotic therapy conducted in our case is also essential for therapeutic success. </Pgraph><Pgraph>After completed wound healing, dermatological follow-up treatment should be continued in our experience.</Pgraph><Pgraph>CEM such as MatriDerm<Superscript>®</Superscript> or Integra<Superscript>®</Superscript> are often associated with high costs and are therefore not ubiquitously available in all healthcare systems worldwide. This limited availability restricts their widespread use, particularly in resource-limited regions, and thus represents a significant barrier to broad clinical application.</Pgraph><Pgraph>In summary, the application of MatriDerm<Superscript>®</Superscript> after radical excision of the affected areas with staged split-thickness skin grafting represents an effective but expensive method for defect reconstruction in penile acne inversa recurrences with high patient satisfaction.</Pgraph></TextBlock>
<TextBlock name="Limitation" linked="yes">
<MainHeadline>Limitation</MainHeadline><Pgraph>This case study has several limitations that should be considered when interpreting the results. Firstly, the investigation is based on a single patient case, which limits the generalizability of the findings. To reliably assess the efficacy and safety of using MatriDerm<Superscript>®</Superscript> for acne inversa defects in the urogenital area, further studies with larger patient cohorts are necessary.</Pgraph><Pgraph>Furthermore, the quality of the quality-of-life measurement in this study is limited, as primarily a simple scale was used, which is only partially suitable for capturing quality of life. In addition, alternative dermal substitute materials and their possible applications in the urogenital region were not examined in detail in this work. A comparative analysis of these products could provide further insights within the scope of a study and support clinical decision-making. To assess the sustainability and long-term outcome, annual follow-up appointments are conducted at our university outpatient clinic. In additional follow-ups after 19 months, no recurrence or deterioration of findings was observed.</Pgraph><Pgraph>Finally, a longer follow-up period would be advisable to make statements about the durability of the reconstruction as well as the risk of recurrence.</Pgraph><Pgraph>Overall, these limitations highlight the need for further research to better define the role of MatriDerm<Superscript>®</Superscript> in urogenital reconstruction for acne inversa and to optimize treatment strategies and associated therapeuti<TextGroup><PlainText>c al</PlainText></TextGroup>gorithms.</Pgraph></TextBlock>
<TextBlock name="Notes" linked="yes">
<MainHeadline>Notes</MainHeadline><SubHeadline>Institutional review board statement</SubHeadline><Pgraph>The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of TU Dresden.</Pgraph><SubHeadline>Informed consent</SubHeadline><Pgraph>Written informed consent to publish the paper and the image files has been obtained from the patient.</Pgraph><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph></TextBlock>
<References linked="yes">
<Reference refNo="1">
<RefAuthor>Fimmel S</RefAuthor>
<RefAuthor>Zouboulis CC</RefAuthor>
<RefTitle>Comorbidities of hidradenitis suppurativa (acne inversa)</RefTitle>
<RefYear>2010</RefYear>
<RefJournal>Dermatoendocrinol</RefJournal>
<RefPage>9-16</RefPage>
<RefTotal>Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010 Jan;2(1):9-16.
DOI: 10.4161/derm.2.1.12490</RefTotal>
<RefLink>https://doi.org/10.4161/derm.2.1.12490</RefLink>
</Reference>
<Reference refNo="2">
<RefAuthor>Kurzen H</RefAuthor>
<RefAuthor>Kurokawa I</RefAuthor>
<RefAuthor>Jemec GB</RefAuthor>
<RefAuthor>Emtestam L</RefAuthor>
<RefAuthor>Sellheyer K</RefAuthor>
<RefAuthor>Giamarellos-Bourboulis EJ</RefAuthor>
<RefAuthor>Nagy I</RefAuthor>
<RefAuthor>Bechara FG</RefAuthor>
<RefAuthor>Sartorius K</RefAuthor>
<RefAuthor>Lapins J</RefAuthor>
<RefAuthor>Krahl D</RefAuthor>
<RefAuthor>Altmeyer P</RefAuthor>
<RefAuthor>Revuz J</RefAuthor>
<RefAuthor>Zouboulis CC</RefAuthor>
<RefTitle>What causes hidradenitis suppurativa?</RefTitle>
<RefYear>2008</RefYear>
<RefJournal>Exp Dermatol</RefJournal>
<RefPage>455-6; discussion 457-72</RefPage>
<RefTotal>Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, Nagy I, Bechara FG, Sartorius K, Lapins J, Krahl D, Altmeyer P, Revuz J, Zouboulis CC. What causes hidradenitis suppurativa? Exp Dermatol. 2008 May;17(5):455-6; discussion 457-72. DOI: 10.1111/j.1600-0625.2008.00712_1.x</RefTotal>
<RefLink>https://doi.org/10.1111/j.1600-0625.2008.00712_1.x</RefLink>
</Reference>
<Reference refNo="3">
<RefAuthor>Naldi L</RefAuthor>
<RefTitle>Epidemiology</RefTitle>
<RefYear>2006</RefYear>
<RefBookTitle>Hidradenitis Suppurativa</RefBookTitle>
<RefPage>58-64</RefPage>
<RefTotal>Naldi L. Epidemiology. In: Jemec GBE, Revuz J, Leyden JJ, editors. Hidradenitis Suppurativa. Berlin, Heidelberg: Springer; 2006.
p. 58-64. DOI: 10.1007/978-3-540-33101-8_8</RefTotal>
<RefLink>https://doi.org/10.1007/978-3-540-33101-8_8</RefLink>
</Reference>
<Reference refNo="4">
<RefAuthor>Revuz JE</RefAuthor>
<RefAuthor>Canoui-Poitrine F</RefAuthor>
<RefAuthor>Wolkenstein P</RefAuthor>
<RefAuthor>Viallette C</RefAuthor>
<RefAuthor>Gabison G</RefAuthor>
<RefAuthor>Pouget F</RefAuthor>
<RefAuthor>Poli F</RefAuthor>
<RefAuthor>Faye O</RefAuthor>
<RefAuthor>Roujeau JC</RefAuthor>
<RefAuthor>Bonnelye G</RefAuthor>
<RefAuthor>Grob JJ</RefAuthor>
<RefAuthor>Bastuji-Garin S</RefAuthor>
<RefTitle>Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies</RefTitle>
<RefYear>2008</RefYear>
<RefJournal>J Am Acad Dermatol</RefJournal>
<RefPage>596-601</RefPage>
<RefTotal>Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008 Oct;59(4):596-601.
DOI: 10.1016/j.jaad.2008.06.020</RefTotal>
<RefLink>https://doi.org/10.1016/j.jaad.2008.06.020</RefLink>
</Reference>
<Reference refNo="5">
<RefAuthor>Jemec GB</RefAuthor>
<RefAuthor>Heidenheim M</RefAuthor>
<RefAuthor>Nielsen NH</RefAuthor>
<RefTitle>The prevalence of hidradenitis suppurativa and its potential precursor lesions</RefTitle>
<RefYear>1996</RefYear>
<RefJournal>J Am Acad Dermatol</RefJournal>
<RefPage>191-4</RefPage>
<RefTotal>Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions.
J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):191-4.
DOI: 10.1016/s0190-9622(96)90321-7</RefTotal>
<RefLink>https://doi.org/10.1016/s0190-9622(96)90321-7</RefLink>
</Reference>
<Reference refNo="6">
<RefAuthor>Revuz J</RefAuthor>
<RefTitle>Hidradenitis suppurativa</RefTitle>
<RefYear>2009</RefYear>
<RefJournal>J Eur Acad Dermatol Venereol</RefJournal>
<RefPage>985-98</RefPage>
<RefTotal>Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009 Sep;23(9):985-98. DOI: 10.1111/j.1468-3083.2009.03356.x</RefTotal>
<RefLink>https://doi.org/10.1111/j.1468-3083.2009.03356.x</RefLink>
</Reference>
<Reference refNo="7">
<RefAuthor>Yu CC</RefAuthor>
<RefAuthor>Cook MG</RefAuthor>
<RefTitle>Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands</RefTitle>
<RefYear>1990</RefYear>
<RefJournal>Br J Dermatol</RefJournal>
<RefPage>763-9</RefPage>
<RefTotal>Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990 Jun;122(6):763-9. DOI: 10.1111/j.1365-2133.1990.tb06264.x</RefTotal>
<RefLink>https://doi.org/10.1111/j.1365-2133.1990.tb06264.x</RefLink>
</Reference>
<Reference refNo="8">
<RefAuthor>Buimer MG</RefAuthor>
<RefAuthor>Wobbes T</RefAuthor>
<RefAuthor>Klinkenbijl JH</RefAuthor>
<RefTitle>Hidradenitis suppurativa</RefTitle>
<RefYear>2009</RefYear>
<RefJournal>Br J Surg</RefJournal>
<RefPage>350-60</RefPage>
<RefTotal>Buimer MG, Wobbes T, Klinkenbijl JH. Hidradenitis suppurativa. Br J Surg. 2009 Apr;96(4):350-60. DOI: 10.1002/bjs.6569</RefTotal>
<RefLink>https://doi.org/10.1002/bjs.6569</RefLink>
</Reference>
<Reference refNo="10">
<RefAuthor>Clemmensen OJ</RefAuthor>
<RefTitle>Topical treatment of hidradenitis suppurativa with clindamycin</RefTitle>
<RefYear>1983</RefYear>
<RefJournal>Int J Dermatol</RefJournal>
<RefPage>325-8</RefPage>
<RefTotal>Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983 Jun;22(5):325-8.
DOI: 10.1111/j.1365-4362.1983.tb02150.x</RefTotal>
<RefLink>https://doi.org/10.1111/j.1365-4362.1983.tb02150.x</RefLink>
</Reference>
<Reference refNo="11">
<RefAuthor>Hazen PG</RefAuthor>
<RefAuthor>Hazen BP</RefAuthor>
<RefTitle>Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization</RefTitle>
<RefYear>2010</RefYear>
<RefJournal>Dermatol Surg</RefJournal>
<RefPage>208-13</RefPage>
<RefTotal>Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010 Feb;36(2):208-13.
DOI: 10.1111/j.1524-4725.2009.01427.x</RefTotal>
<RefLink>https://doi.org/10.1111/j.1524-4725.2009.01427.x</RefLink>
</Reference>
<Reference refNo="12">
<RefAuthor>Kleintjes WG</RefAuthor>
<RefTitle>The horizontal reconstructive ladder</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>South African Journal of Plastic & Reconstructive Aesthetic Surgery & Burns</RefJournal>
<RefPage>19</RefPage>
<RefTotal>Kleintjes WG. The horizontal reconstructive ladder. South African Journal of Plastic & Reconstructive Aesthetic Surgery & Burns. 2018;1(1):19. DOI: 10.7196/sajprasb.1383</RefTotal>
<RefLink>https://doi.org/10.7196/sajprasb.1383</RefLink>
</Reference>
<Reference refNo="13">
<RefAuthor>Herskovitz I</RefAuthor>
<RefAuthor>Hughes OB</RefAuthor>
<RefAuthor>Macquhae F</RefAuthor>
<RefAuthor>Rakosi A</RefAuthor>
<RefAuthor>Kirsner R</RefAuthor>
<RefTitle>Epidermal skin grafting</RefTitle>
<RefYear>2016</RefYear>
<RefJournal>Int Wound J</RefJournal>
<RefPage>52-6</RefPage>
<RefTotal>Herskovitz I, Hughes OB, Macquhae F, Rakosi A, Kirsner R. Epidermal skin grafting. Int Wound J. 2016 Sep;13 Suppl 3(Suppl 3):52-6. DOI: 10.1111/iwj.12631</RefTotal>
<RefLink>https://doi.org/10.1111/iwj.12631</RefLink>
</Reference>
<Reference refNo="14">
<RefAuthor>Killat J</RefAuthor>
<RefAuthor>Reimers K</RefAuthor>
<RefAuthor>Choi CY</RefAuthor>
<RefAuthor>Jahn S</RefAuthor>
<RefAuthor>Vogt PM</RefAuthor>
<RefAuthor>Radtke C</RefAuthor>
<RefTitle>Cultivation of keratinocytes and fibroblasts in a three-dimensional bovine collagen-elastin matrix (Matriderm®) and application for full thickness wound coverage in vivo</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>Int J Mol Sci</RefJournal>
<RefPage>14460-74</RefPage>
<RefTotal>Killat J, Reimers K, Choi CY, Jahn S, Vogt PM, Radtke C. Cultivation of keratinocytes and fibroblasts in a three-dimensional bovine collagen-elastin matrix (Matriderm®) and application for full thickness wound coverage in vivo. Int J Mol Sci. 2013 Jul;14(7):14460-74. DOI: 10.3390/ijms140714460</RefTotal>
<RefLink>https://doi.org/10.3390/ijms140714460</RefLink>
</Reference>
<Reference refNo="15">
<RefAuthor>Min JH</RefAuthor>
<RefAuthor>Yun IS</RefAuthor>
<RefAuthor>Lew DH</RefAuthor>
<RefAuthor>Roh TS</RefAuthor>
<RefAuthor>Lee WJ</RefAuthor>
<RefTitle>The use of matriderm and autologous skin graft in the treatment of full thickness skin defects</RefTitle>
<RefYear>2014</RefYear>
<RefJournal>Arch Plast Surg</RefJournal>
<RefPage>330-6</RefPage>
<RefTotal>Min JH, Yun IS, Lew DH, Roh TS, Lee WJ. The use of matriderm and autologous skin graft in the treatment of full thickness skin defects. Arch Plast Surg. 2014 Jul;41(4):330-6.
DOI: 10.5999/aps.2014.41.4.330</RefTotal>
<RefLink>https://doi.org/10.5999/aps.2014.41.4.330</RefLink>
</Reference>
<Reference refNo="16">
<RefAuthor>Alawi SA</RefAuthor>
<RefAuthor>Taqatqeh F</RefAuthor>
<RefAuthor>Matschke J</RefAuthor>
<RefAuthor>Bota O</RefAuthor>
<RefAuthor>Dragu A</RefAuthor>
<RefTitle>Use of a collagen-elastin matrix with split-thickness skin graft for defect coverage in complex wounds</RefTitle>
<RefYear>2024</RefYear>
<RefJournal>J Wound Care</RefJournal>
<RefPage>14-21</RefPage>
<RefTotal>Alawi SA, Taqatqeh F, Matschke J, Bota O, Dragu A. Use of a collagen-elastin matrix with split-thickness skin graft for defect coverage in complex wounds. J Wound Care. 2024 Jan;33(1):14-21. DOI: 10.12968/jowc.2024.33.1.14</RefTotal>
<RefLink>https://doi.org/10.12968/jowc.2024.33.1.14</RefLink>
</Reference>
<Reference refNo="17">
<RefAuthor>Tchero H</RefAuthor>
<RefAuthor>Herlin C</RefAuthor>
<RefAuthor>Bekara F</RefAuthor>
<RefAuthor>Kangambega P</RefAuthor>
<RefAuthor>Sergiu F</RefAuthor>
<RefAuthor>Teot L</RefAuthor>
<RefTitle>Failure rates of artificial dermis products in treatment of diabetic foot ulcer: A systematic review and network meta-analysis</RefTitle>
<RefYear>2017</RefYear>
<RefJournal>Wound Repair Regen</RefJournal>
<RefPage>691-6</RefPage>
<RefTotal>Tchero H, Herlin C, Bekara F, Kangambega P, Sergiu F, Teot L. Failure rates of artificial dermis products in treatment of diabetic foot ulcer: A systematic review and network meta-analysis. Wound Repair Regen. 2017 Aug;25(4):691-6. DOI: 10.1111/wrr.12554</RefTotal>
<RefLink>https://doi.org/10.1111/wrr.12554</RefLink>
</Reference>
<Reference refNo="18">
<RefAuthor>Kolokythas P</RefAuthor>
<RefAuthor>Aust MC</RefAuthor>
<RefAuthor>Vogt PM</RefAuthor>
<RefAuthor>Paulsen F</RefAuthor>
<RefTitle>Aktuelle Ubersicht zum Dermisersatz mit Kollagen-Elastin-Matrix Matriderm bei Brandverletzungen</RefTitle>
<RefYear>2008</RefYear>
<RefJournal>Handchir Mikrochir Plast Chir</RefJournal>
<RefPage>367-71</RefPage>
<RefTotal>Kolokythas P, Aust MC, Vogt PM, Paulsen F. Aktuelle Ubersicht zum Dermisersatz mit Kollagen-Elastin-Matrix Matriderm bei Brandverletzungen [Dermal subsitute with the collagen-elastin matrix Matriderm in burn injuries: a comprehensive review]. Handchir Mikrochir Plast Chir. 2008 Dec;40(6):367-71.
DOI: 10.1055/s-2008-1038459</RefTotal>
<RefLink>https://doi.org/10.1055/s-2008-1038459</RefLink>
</Reference>
<Reference refNo="19">
<RefAuthor>Delli Santi G</RefAuthor>
<RefAuthor>La Greca C</RefAuthor>
<RefAuthor>Bruno A</RefAuthor>
<RefAuthor>Palombo M</RefAuthor>
<RefAuthor>Bronco I</RefAuthor>
<RefAuthor>Palombo P</RefAuthor>
<RefTitle>The Use of Dermal Regeneration Template (Matriderm® 1 mm) for Reconstruction of a Large Full-Thickness Scalp and Calvaria Exposure</RefTitle>
<RefYear>2016</RefYear>
<RefJournal>J Burn Care Res</RefJournal>
<RefPage>e497-8</RefPage>
<RefTotal>Delli Santi G, La Greca C, Bruno A, Palombo M, Bronco I, Palombo P. The Use of Dermal Regeneration Template (Matriderm®
1 mm) for Reconstruction of a Large Full-Thickness Scalp and Calvaria Exposure. J Burn Care Res. 2016;37(5):e497-8.
DOI: 10.1097/BCR.0000000000000395</RefTotal>
<RefLink>https://doi.org/10.1097/BCR.0000000000000395</RefLink>
</Reference>
<Reference refNo="9">
<RefAuthor>Dickson K</RefAuthor>
<RefAuthor>Lee KC</RefAuthor>
<RefAuthor>Abdulsalam A</RefAuthor>
<RefAuthor>Amirize E</RefAuthor>
<RefAuthor>Kankam HKN</RefAuthor>
<RefAuthor>Ter Horst B</RefAuthor>
<RefAuthor>Gardiner F</RefAuthor>
<RefAuthor>Bamford A</RefAuthor>
<RefAuthor>Hejmadi RK</RefAuthor>
<RefAuthor>Moiemen N</RefAuthor>
<RefTitle>A Histological and Clinical Study of MatriDerm® Use in Burn Reconstruction</RefTitle>
<RefYear>2023</RefYear>
<RefJournal>J Burn Care Res</RefJournal>
<RefPage>1100-9</RefPage>
<RefTotal>Dickson K, Lee KC, Abdulsalam A, Amirize E, Kankam HKN, Ter Horst B, Gardiner F, Bamford A, Hejmadi RK, Moiemen N. A Histological and Clinical Study of MatriDerm® Use in Burn Reconstruction. J Burn Care Res. 2023 Sep;44(5):1100-9.
DOI: 10.1093/jbcr/irad024</RefTotal>
<RefLink>https://doi.org/10.1093/jbcr/irad024</RefLink>
</Reference>
<Reference refNo="20">
<RefAuthor>Ludolph I</RefAuthor>
<RefAuthor>Titel T</RefAuthor>
<RefAuthor>Beier JP</RefAuthor>
<RefAuthor>Dragu A</RefAuthor>
<RefAuthor>Schmitz M</RefAuthor>
<RefAuthor>Wullich B</RefAuthor>
<RefAuthor>Horch RE</RefAuthor>
<RefTitle>Penile reconstruction with dermal template and vacuum therapy in severe skin and soft tissue defects caused by Fournier's gangrene and hidradenitis suppurativa</RefTitle>
<RefYear>2016</RefYear>
<RefJournal>Int Wound J</RefJournal>
<RefPage>77-81</RefPage>
<RefTotal>Ludolph I, Titel T, Beier JP, Dragu A, Schmitz M, Wullich B, Horch RE. Penile reconstruction with dermal template and vacuum therapy in severe skin and soft tissue defects caused by Fournier's gangrene and hidradenitis suppurativa. Int Wound J. 2016 Feb;13(1):77-81. DOI: 10.1111/iwj.12235</RefTotal>
<RefLink>https://doi.org/10.1111/iwj.12235</RefLink>
</Reference>
<Reference refNo="21">
<RefAuthor>Wang Y</RefAuthor>
<RefAuthor>Wang G</RefAuthor>
<RefAuthor>Hou X</RefAuthor>
<RefAuthor>Zhao Y</RefAuthor>
<RefAuthor>Chen B</RefAuthor>
<RefAuthor>Dai J</RefAuthor>
<RefAuthor>Sun N</RefAuthor>
<RefTitle>Urethral Tissue Reconstruction Using the Acellular Dermal Matrix Patch Modified with Collagen-Binding VEGF in Beagle Urethral Injury Models</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>Biomed Res Int</RefJournal>
<RefPage>5502740</RefPage>
<RefTotal>Wang Y, Wang G, Hou X, Zhao Y, Chen B, Dai J, Sun N. Urethral Tissue Reconstruction Using the Acellular Dermal Matrix Patch Modified with Collagen-Binding VEGF in Beagle Urethral Injury Models. Biomed Res Int. 2021;2021:5502740.
DOI: 10.1155/2021/5502740</RefTotal>
<RefLink>https://doi.org/10.1155/2021/5502740</RefLink>
</Reference>
<Reference refNo="22">
<RefAuthor>Poli F</RefAuthor>
<RefAuthor>Jemec GBE</RefAuthor>
<RefAuthor>Revuz J</RefAuthor>
<RefTitle>Clinical Presentation</RefTitle>
<RefYear>2006</RefYear>
<RefBookTitle>Hidradenitis Suppurativa</RefBookTitle>
<RefPage>11-24</RefPage>
<RefTotal>Poli F, Jemec GBE, Revuz J. Clinical Presentation. In: Jemec GBE, Revuz J, Leyden JJ, editors. Hidradenitis Suppurativa. Berlin, Heidelberg:Springer;2006. p. 11-24. DOI: 10.1007/978-3-540-33101-8_3</RefTotal>
<RefLink>https://doi.org/10.1007/978-3-540-33101-8_3</RefLink>
</Reference>
<Reference refNo="23">
<RefAuthor>Alikhan A</RefAuthor>
<RefAuthor>Lynch PJ</RefAuthor>
<RefAuthor>Eisen DB</RefAuthor>
<RefTitle>Hidradenitis suppurativa: a comprehensive review</RefTitle>
<RefYear>2009</RefYear>
<RefJournal>J Am Acad Dermatol</RefJournal>
<RefPage>539-61; quiz 562-3</RefPage>
<RefTotal>Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3. DOI: 10.1016/j.jaad.2008.11.911</RefTotal>
<RefLink>https://doi.org/10.1016/j.jaad.2008.11.911</RefLink>
</Reference>
</References>
<Media>
<Tables>
<NoOfTables>0</NoOfTables>
</Tables>
<Figures>
<Figure width="1226" height="487" format="png">
<MediaNo>1</MediaNo>
<MediaID>1</MediaID>
<Caption><Pgraph><Mark1>Figure 1: Preoperative situation of the recurrence</Mark1></Pgraph></Caption>
</Figure>
<Figure width="1211" height="500" format="png">
<MediaNo>2</MediaNo>
<MediaID>2</MediaID>
<Caption><Pgraph><Mark1>Figure 2: Intraoperative finding: 1</Mark1><Mark1><Superscript>st</Superscript></Mark1><Mark1> debridement</Mark1></Pgraph></Caption>
</Figure>
<Figure width="898" height="493" format="png">
<MediaNo>3</MediaNo>
<MediaID>3</MediaID>
<Caption><Pgraph><Mark1>Figure 3: Intraoperative application of MatriDerm</Mark1><Mark1><Superscript>®</Superscript></Mark1><Mark1> and skin graft</Mark1></Pgraph></Caption>
</Figure>
<Figure width="928" height="491" format="png">
<MediaNo>4</MediaNo>
<MediaID>4</MediaID>
<Caption><Pgraph><Mark1>Figure 4: Five days postoperative</Mark1></Pgraph></Caption>
</Figure>
<Figure width="1155" height="302" format="png">
<MediaNo>5</MediaNo>
<MediaID>5</MediaID>
<Caption><Pgraph><Mark1>Figure 5: Results 6 months postoperative</Mark1></Pgraph></Caption>
</Figure>
<Figure width="1194" height="305" format="png">
<MediaNo>6</MediaNo>
<MediaID>6</MediaID>
<Caption><Pgraph><Mark1>Figure 6: Results 12 months postoperative</Mark1></Pgraph></Caption>
</Figure>
<NoOfPictures>6</NoOfPictures>
</Figures>
<InlineFigures>
<NoOfPictures>0</NoOfPictures>
</InlineFigures>
<Attachments>
<NoOfAttachments>0</NoOfAttachments>
</Attachments>
</Media>
</OrigData>
</GmsArticle>]]></plaintext></textgroup></pgraph></abstract></origdata></gmsarticle>